Skip to main content

Advertisement

ADVERTISEMENT

News

FDA Approval
07/01/2024
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new drug application for SH-105, a liquid formulation of thiotepa, for the treatment of patients with breast and ovarian cancer.
The FDA has approved the new...
07/01/2024
Oncology
News
06/18/2024
Allison Casey
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology
News
06/18/2024
Allison Casey
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the phase 3 CARACO trial, the omission of retroperitoneal and paraaortic lymphadenectomy during surgery for advanced epithelial ovarian cancer did not negative impact survival outcomes and reduced the frequency of...
According to results from the...
06/18/2024
Oncology

Advertisement

Conference Coverage
06/13/2024
Allison Casey
According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.
According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.
According to phase 2 results,...
06/13/2024
Oncology
Conference Coverage
06/13/2024
Allison Casey
Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.
Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.
Results from the phase 3 SCORES...
06/13/2024
Oncology
Conference Coverage
06/03/2024
Allison Casey
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...
According to phase 2 data to be...
06/03/2024
Oncology

Advertisement

Conference Coverage
03/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the...
03/16/2024
Oncology
Conference Coverage
03/16/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the phase 2 UPLIFT trial, upifitamab rilsodoti did not significantly improve objective response rate compared to standard single-agent chemotherapy among patients with previously treated platinum-resistant ovarian...
According to results from the...
03/16/2024
Oncology
News
02/09/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 3 MITO-23 study demonstrated trabectedin did not improve overall survival and showed a worse safety profile compared to standard chemotherapy among patients with recurrent ovarian cancer and BRCA-mutation/BRCAness...
Results from the phase 3 MITO-23 study demonstrated trabectedin did not improve overall survival and showed a worse safety profile compared to standard chemotherapy among patients with recurrent ovarian cancer and BRCA-mutation/BRCAness...
Results from the phase 3 MITO-23...
02/09/2024
Oncology

Advertisement

News
12/19/2023

Stephanie Holland 

Stephanie Holland 
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved progression-free survival (PFS), overall survival (OS), and objective response, compared with chemotherapy among patients with...
According to results from the...
12/19/2023
Oncology

Advertisement